Ionis Pharmaceuticals, Inc.

NasdaqGS:IONS 株式レポート

時価総額：US$6.1b

Ionis Pharmaceuticals マネジメント

マネジメント 基準チェック /24

Ionis Pharmaceuticalsの CEO はBrett Moniaで、 Jan2020年に任命され、 の在任期間は 4.83年です。 の年間総報酬は$ 12.50Mで、 7.7%給与と92.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.11%を直接所有しており、その価値は$ 6.74M 。経営陣と取締役会の平均在任期間はそれぞれ4.8年と8.5年です。

主要情報

Brett Monia

最高経営責任者

US$12.5m

報酬総額

CEO給与比率7.7%
CEO在任期間4.8yrs
CEOの所有権0.1%
経営陣の平均在職期間4.8yrs
取締役会の平均在任期間8.5yrs

経営陣の近況

Recent updates

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24
There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28
Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Dec 07
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Nov 16
A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Aug 03
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

May 05
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Jan 20
Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Ionis Pharmaceuticals Looks Good For The Long Term

Oct 19

Ionis plans for new manufacturing site in California to support pipeline

Oct 13

Ionis: 2 Drug Advancements With Potential Firsts

Aug 29

Ionis Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt

Aug 08
Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt

CEO報酬分析

Ionis Pharmaceuticals の収益と比較して、Brett Monia の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$366m

Mar 31 2024n/an/a

-US$385m

Dec 31 2023US$13mUS$961k

-US$366m

Sep 30 2023n/an/a

-US$409m

Jun 30 2023n/an/a

-US$309m

Mar 31 2023n/an/a

-US$329m

Dec 31 2022US$7mUS$825k

-US$270m

Sep 30 2022n/an/a

US$7m

Jun 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$13mUS$800k

-US$29m

Sep 30 2021n/an/a

-US$608m

Jun 30 2021n/an/a

-US$550m

Mar 31 2021n/an/a

-US$495m

Dec 31 2020US$11mUS$700k

-US$444m

Sep 30 2020n/an/a

US$94m

Jun 30 2020n/an/a

US$145m

Mar 31 2020n/an/a

US$169m

Dec 31 2019US$7mUS$528k

US$281m

Sep 30 2019n/an/a

US$433m

Jun 30 2019n/an/a

US$402m

Mar 31 2019n/an/a

US$366m

Dec 31 2018US$4mUS$508k

US$277m

Sep 30 2018n/an/a

-US$41m

Jun 30 2018n/an/a

-US$38m

Mar 31 2018n/an/a

US$9m

Dec 31 2017US$2mUS$443k

US$19m

報酬と市場: Brettの 総報酬 ($USD 12.50M ) は、 US市場 ($USD 8.06M ) の同規模の企業の平均を上回っています。

報酬と収益: Brettの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Brett Monia (63 yo)

4.8yrs

在職期間

US$12,500,023

報酬

Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Brett Monia
Founder4.8yrsUS$12.50m0.11%
$ 6.7m
Elizabeth Hougen
Executive VP of Finance & CFO11.8yrsUS$2.89m0.059%
$ 3.6m
B. Parshall
Director6.8yrsUS$538.04k0.055%
$ 3.4m
Richard Geary
Executive VP & Chief Development Officer16.3yrsUS$2.56m0.054%
$ 3.3m
Eric Swayze
Executive Vice President of Research4.8yrsUS$2.56m0.022%
$ 1.4m
Darren Gonzales
Chief Accounting Officer & Senior VP4.8yrsデータなしデータなし
C. Bennett
Executive VP & Chief Scientific Officer4.8yrsUS$958.87k0.051%
$ 3.1m
D. Walke
Senior Vice President of Investor Relationsno dataデータなしデータなし
Patrick O'Neil
Executive VP11.8yrsUS$3.92m0.031%
$ 1.9m
Hayley Soffer
Vice President of Corporate Communicationsless than a yearデータなしデータなし
Shannon Devers
Senior Vice President of Human Resources4.8yrsデータなし0.0050%
$ 306.5k
Stanley Crooke
Scientific Advisor3.4yrsUS$2.28mデータなし

4.8yrs

平均在職期間

64.5yo

平均年齢

経験豊富な経営陣: IONSの経営陣は 経験豊富 であると考えられます ( 4.8年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Brett Monia
Founder5.7yrsUS$12.50m0.11%
$ 6.7m
B. Parshall
Director24.2yrsUS$538.04k0.055%
$ 3.4m
Joan Herman
Independent Director5.4yrsUS$540.04k0.027%
$ 1.6m
Joseph Klein
Independent Director18.9yrsUS$542.04k0.010%
$ 637.4k
Joseph Wender
Lead Independent Director30.8yrsUS$598.04k0.084%
$ 5.1m
Michael Hayden
Independent Director6.2yrsUS$528.04k0.020%
$ 1.2m
Spencer Berthelsen
Independent Director22.5yrsUS$548.04k0.097%
$ 5.9m
Joseph Loscalzo
Independent Chairman of the Board10.8yrsUS$568.04k0.029%
$ 1.8m
Allene Diaz
Independent Director3.4yrsUS$530.04k0.010%
$ 609.3k
Michael Yang
Independent Directorless than a yearUS$363.05kデータなし

8.5yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: IONSの 取締役会 は 経験豊富 であると考えられます ( 8.5年の平均在任期間)。